vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and Roper Technologies (ROP). Click either name above to swap in a different company.
Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.2B, roughly 1.7× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 15.8%, a 1.2% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 10.1%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $345.8M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 10.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
JAZZ vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.1B |
| Net Profit | $203.5M | $331.0M |
| Gross Margin | — | 69.4% |
| Operating Margin | 21.2% | 27.2% |
| Net Margin | 17.0% | 15.8% |
| Revenue YoY | 10.1% | 11.3% |
| Net Profit YoY | 6.5% | 53.7% |
| EPS (diluted) | $3.34 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $897.8M | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $203.5M | $428.4M | ||
| Q3 25 | $251.4M | $398.5M | ||
| Q2 25 | $-718.5M | $378.3M | ||
| Q1 25 | $-92.5M | $331.1M | ||
| Q4 24 | $191.1M | $462.3M | ||
| Q3 24 | $215.1M | $367.9M | ||
| Q2 24 | $168.6M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | — | 69.5% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 69.2% | ||
| Q1 25 | — | 68.7% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 69.2% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 21.2% | 28.6% | ||
| Q3 25 | 5.1% | 28.4% | ||
| Q2 25 | -65.6% | 28.2% | ||
| Q1 25 | -6.2% | 27.9% | ||
| Q4 24 | 17.5% | 28.0% | ||
| Q3 24 | 24.7% | 28.1% | ||
| Q2 24 | 19.5% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 17.0% | 20.8% | ||
| Q3 25 | 22.3% | 19.8% | ||
| Q2 25 | -68.7% | 19.5% | ||
| Q1 25 | -10.3% | 17.6% | ||
| Q4 24 | 17.6% | 24.6% | ||
| Q3 24 | 20.4% | 20.8% | ||
| Q2 24 | 16.5% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $3.34 | $3.97 | ||
| Q3 25 | $4.08 | $3.68 | ||
| Q2 25 | $-11.74 | $3.49 | ||
| Q1 25 | $-1.52 | $3.06 | ||
| Q4 24 | $2.97 | $4.29 | ||
| Q3 24 | $3.42 | $3.40 | ||
| Q2 24 | $2.49 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $382.9M |
| Total DebtLower is stronger | $5.4B | $9.7B |
| Stockholders' EquityBook value | $4.3B | $18.8B |
| Total Assets | $11.7B | $34.6B |
| Debt / EquityLower = less leverage | 1.24× | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $1.4B | $297.4M | ||
| Q3 25 | $1.3B | $320.0M | ||
| Q2 25 | $1.2B | $242.4M | ||
| Q1 25 | $1.9B | $372.8M | ||
| Q4 24 | $2.4B | $188.2M | ||
| Q3 24 | $2.2B | $269.6M | ||
| Q2 24 | $1.4B | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | $5.4B | $9.3B | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | $7.6B | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $4.3B | $19.9B | ||
| Q3 25 | $4.0B | $20.0B | ||
| Q2 25 | $3.7B | $19.6B | ||
| Q1 25 | $4.2B | $19.2B | ||
| Q4 24 | $4.1B | $18.9B | ||
| Q3 24 | $4.2B | $18.5B | ||
| Q2 24 | $3.8B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $11.7B | $34.6B | ||
| Q3 25 | $11.4B | $34.6B | ||
| Q2 25 | $10.9B | $33.2B | ||
| Q1 25 | $11.5B | $31.4B | ||
| Q4 24 | $12.0B | $31.3B | ||
| Q3 24 | $12.3B | $31.6B | ||
| Q2 24 | $11.4B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | 1.24× | 0.47× | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | 0.40× | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | — |
| Free Cash FlowOCF − Capex | $345.8M | $507.0M |
| FCF MarginFCF / Revenue | 28.9% | 24.2% |
| Capex IntensityCapex / Revenue | 1.4% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $362.5M | $738.0M | ||
| Q3 25 | $474.6M | $869.5M | ||
| Q2 25 | $88.9M | $404.1M | ||
| Q1 25 | $429.8M | $528.7M | ||
| Q4 24 | $398.6M | $722.2M | ||
| Q3 24 | $398.7M | $755.4M | ||
| Q2 24 | $331.4M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $345.8M | — | ||
| Q3 25 | $459.4M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | — | ||
| Q4 24 | $385.3M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $324.3M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 31.7% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | 1.72× | ||
| Q3 25 | 1.89× | 2.18× | ||
| Q2 25 | — | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 2.09× | 1.56× | ||
| Q3 24 | 1.85× | 2.05× | ||
| Q2 24 | 1.97× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
ROP
Segment breakdown not available.
